1. Home
  2. TWLO vs GMAB Comparison

TWLO vs GMAB Comparison

Compare TWLO & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twilio Inc.

TWLO

Twilio Inc.

HOLD

Current Price

$123.90

Market Cap

17.3B

Sector

Technology

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$29.53

Market Cap

19.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWLO
GMAB
Founded
2008
1999
Country
United States
Denmark
Employees
5535
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.3B
19.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TWLO
GMAB
Price
$123.90
$29.53
Analyst Decision
Buy
Strong Buy
Analyst Count
25
7
Target Price
$143.00
$41.08
AVG Volume (30 Days)
3.0M
1.5M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.36
$15.54
Revenue Next Year
$8.03
$14.29
P/E Ratio
$526.76
$1.90
Revenue Growth
N/A
N/A
52 Week Low
$77.51
$17.24
52 Week High
$145.90
$35.43

Technical Indicators

Market Signals
Indicator
TWLO
GMAB
Relative Strength Index (RSI) 56.71 40.25
Support Level $123.00 $28.17
Resistance Level $135.90 $33.75
Average True Range (ATR) 6.50 0.75
MACD 1.89 0.01
Stochastic Oscillator 90.92 44.78

Price Performance

Historical Comparison
TWLO
GMAB

About TWLO Twilio Inc.

Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: